One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 1months
-
http://medilib.ir
- Duration of Time : 31 Day
Price : 100$- Special Price : 50$
The SCIENCE trial: surgery or not for medial epicondyle fractures.
TRPC6 inhibition: podocyte-targeted treatment for focal segmental glomerulosclerosis?
Beyond integrase: the rise of doravirine and islatravir in HIV management.
A risk to child health: confusion and concern over changes to US vaccine policy.
Announcing the Lancet Commission on Maternal and Newborn Health.
Millions of Americans lose health insurance as COVID-19 era subsidies end
Improvisation in contexts of infrastructural violence: a physician practising medicine in Sahrawi refugee camps.
US forced deportation, language exclusion, and disability justice.
Simplifying and improving heart attack and stroke prevention – Authors' reply.
Response to STRIDE: semaglutide in peripheral artery disease and type 2 diabetes.
Response to STRIDE: semaglutide in peripheral artery disease and type 2 diabetes – Authors' reply.
Improving cancer surveillance and global cancer burden estimates.
Improving cancer surveillance and global cancer burden estimates.
Improving cancer surveillance and global cancer burden estimates – Author's reply.
Surgical fixation versus non-surgical care for children with a displaced medial epicondyle fracture of the elbow (the SCIENCE study): a multicentre, randomised controlled, superiority trial and economic evaluation.
TRPC6 inhibition for the treatment of focal segmental glomerulosclerosis: a randomised, placebo-controlled, phase 2 trial of BI 764198.
Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial.
Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial.
VEXAS syndrome: a comprehensive review of pathogenesis, clinical spectrum, and therapeutic strategies.
